Brian Peppers
Allergy & Immunology · Morgantown, WVNPI 1558660480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 25.7% of the total. Reporting peaked in 2022 at $556 and has fallen 61.4% since, to $214 in 2025.
Across 58 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$411
- AstraZeneca$297
- Biocryst US Sales Co., LLC$178
- Novartis$93
- Regeneron Healthcare Solutions, Inc.$93
- Takeda Pharmaceuticals U.S.A., Inc.$89
- plus $439 from 10 others
Across 4 payments — averaging $8637.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$19K
- Eli Lilly$16K
What the payments were for
- Food & beverage$1,56498%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $411 |
| AstraZeneca | 9 | $297 |
| Biocryst US Sales Co., LLC | 7 | $178 |
| Novartis | 3 | $93 |
| Regeneron Healthcare Solutions, Inc. | 2 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Grifols USA, LLC | 3 | $83 |
| Sanofi | 1 | $82 |
| Pfizer | 3 | $56 |
| Shire North American Group Inc | 2 | $47 |
| Genentech USA, Inc. | 3 | $46 |
| Pharming Healthcare, Inc. | 2 | $40 |
| CSL Behring | 1 | $36 |
| Kaleo, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Mentor Worldwide LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$125
How this compares
Too few allergy & immunology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 13 | $536,954 |
| NucalaMepolizumab | 25 | $270,445 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $107,818 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $78,612 |
| OtezlaApremilast | 12 | $57,466 |
| Dupixent PenDupilumab | 16 | $55,896 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $25,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,410 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,953 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $3,843 |
| Azithromycin | 215 | $3,088 |
| Ipratropium Bromide | 63 | $1,890 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,285 |
| Hydroxychloroquine Sulfate | 11 | $547 |
| Doxycycline Hyclate | 37 | $544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $36 | $615,56632 claims |
| GSKNucala, Trelegy Ellipta | $411 | $288,85650 claims |
| Grifols USA, LLCGamunex-C | $83 | $107,81840 claims |
| AstraZenecaBreztri Aerosphere | $297 | $25,42026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Morgantown
- William CorderMorgantown$2K
- James ClarkCharleston$144K
- Krishna UrvalWheeling$12K
- Donald AsburyBluefield$9K
- Meagan ShepherdBarboursville$8K
- Siwat KiratiseaveeCharleston$8K
- Lawrence ThrushCharleston$2K
- Nasm SheikhSouth Charleston$1K
- Ardeshir TamboliWeirton$225
- Chandra KumarCharleston$217
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.